ReviewTransfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2019
Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
Review in Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Analysis of Erythrocyte Membrane Alloantigens.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Examination of Antigen-Specific B Cell Responses to Red Blood Cell Transfusion.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Harnessing the potential of red blood cells in immunotherapy.Human immunology · 2024Review
- Article
- ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies.iScience · 2023Review
- Adverse events of red blood cell transfusions in patients with sickle cell disease.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Review
- Erythropoietic properties of human induced pluripotent stem cells-derived red blood cells in immunodeficient mice.American journal of hematology · 2022Article
- How to avoid the problem of erythrocyte alloimmunization in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2021Review
- Are We Forgetting About IgA? A Re-examination of Coronavirus Disease 2019 Convalescent Plasma.Transfusion · 2021Article
- Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.Blood advances · 2021Article
- Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Case Report.International medical case reports journal · 2020Article
- Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.Transfusion medicine reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Red blood cell (RBC) transfusion support represents a critical component of sickle cell disease (SCD) management. However, as with any therapeutic intervention, RBC transfusion is not without risk. Repeat exposure to allogeneic RBCs can result in the development of RBC alloantibodies that can make it difficult to find compatible RBCs for future transfusions and can directly increase the risk of developing acute or delayed hemolytic transfusion reactions, which can be further complicated by hyperhemolysis. Several prophylactic and treatment strategies have been employed in an effort to reduce or prevent hemolytic transfusion reactions. However, conflicting data exist regarding the efficacy of many of these approaches. We will explore the challenges associated with predicting, preventing and treating different types of hemolytic transfusion reactions in patients with SCD in addition to describing future strategies that may aid in the management of the complex transfusion requirements of SCD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.